Paper Details

  1. Home
  2. Paper Details

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.

Author: BaerM R, BergD T, BloomfieldC D, DodgeR K, GeorgeS L, LeeE J, MooreJ O, PaciucciP A, PowellB L, SchifferC A, SchulmanP P, StoneR M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

In a study of 388 people over 60 with newly diagnosed acute myeloid leukemia (AML), there was no benefit to using granulocyte-macrophage colony-stimulating factor (GM-CSF) during initial treatment. After achieving remission, patients were randomly assigned to receive either cytarabine alone or a combination of cytarabine and mitoxantrone. There was no difference in survival or relapse rates between the two groups. The combination therapy was more toxic and offered no advantage over cytarabine alone. This study highlights the need for new treatment approaches for older adults with AML.
Paper Details　
Original Abstract of the Article :
The treatment of older patients with acute myeloid leukemia (AML) remains unsatisfactory, with complete remission (CR) achieved in only approximately 50% and long-term disease-free survival in 10% to 20%. Three hundred eighty-eight patients (60 years of age and older) with newly diagnosed de novo AM...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11468148

データ提供：米国国立医学図書館（NLM）

Post-Remission Therapy for Older Patients with Acute Myeloid Leukemia

Acute myeloid leukemia (AML), a relentless disease, presents a unique challenge for older patients. This research focuses on postremission therapy for this group, exploring the effectiveness of different treatment approaches. The study compares two regimens: cytarabine alone versus a combination of cytarabine and mitoxantrone. While both regimens achieved similar outcomes in terms of disease-free survival, the combination therapy proved more toxic. This research highlights the need for continued investigation into novel therapeutic strategies for older patients with AML, as the current treatment landscape leaves room for improvement.

A Shifting Landscape in Leukemia Treatment

This research emphasizes the need for continued exploration of novel therapeutic strategies for older patients with AML. The authors acknowledge the limitations of current treatment approaches and advocate for the development of new and more effective therapies. The study highlights the ongoing quest for improved treatment options for older patients with AML, a disease that demands innovative solutions.

Seeking New Oases in the Desert of Leukemia

This research serves as a reminder of the ongoing battle against leukemia and the need for continued research and innovation. The authors highlight the need for novel therapeutic strategies, emphasizing the crucial role of research in improving treatment outcomes for patients battling this challenging disease.

Dr.Camel's Conclusion

This study reminds us that the journey to conquer leukemia is far from over. The research highlights the need for continued exploration of novel therapeutic strategies, especially for older patients, who face unique challenges. This research serves as a reminder of the ongoing battle against leukemia, a relentless adversary that requires persistent research and innovation.

Date :
  1. Date Completed 2001-09-13
  2. Date Revised 2021-02-16
Further Info :

Pubmed ID

11468148

DOI: Digital Object Identifier

S0006-4971(20)48049-8

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.